<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1344">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04750369</url>
  </required_header>
  <id_info>
    <org_study_id>20-5225</org_study_id>
    <nct_id>NCT04750369</nct_id>
  </id_info>
  <brief_title>Enhanced Triage for COVID-19</brief_title>
  <acronym>ETC-19</acronym>
  <official_title>Enhanced Triage for COVID-19 to Validate the Rapid Acute Lung Injury Diagnostic (RALI-Dx) Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate of the accuracy of biomarkers (i.e. circulating endothelial and&#xD;
      immune activation markers) that indicate progression to severe disease in patients with&#xD;
      suspected COVID-19 in the Emergency Department. It is a prospective observational study of&#xD;
      patients presenting to emergency departments with a clinical suspicion of COVID19. All&#xD;
      participants will have plasma samples collected for biomarker analysis, and will be tested&#xD;
      for SARS-CoV-2 infection with a nasopharyngeal swab. Participants will be managed according&#xD;
      to the best local practices.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Predictive Accuracy of Biomarkers for Risk Stratification</measure>
    <time_frame>28 days</time_frame>
    <description>Given the expected clinical utility, we will use likelihood ratios (LRs) as our target milestone.&#xD;
+LR = (test sensitivity)/(1-test specificity);&#xD;
-LR= (1- sensitivity)/specificity.&#xD;
We will conservatively target benchmarks of +LR&gt;5 for a disposition towards and a -LR&lt;0.1 for a disposition away from mortality risk.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance of Biomarkers as Indicators of Clinical Severity: Disposition post-ED visit (admitted vs discharged home vs discharged home and readmitted)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of Biomarkers as Indicators of Clinical Severity: Hospital and ICU length of stay</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of Biomarkers as Indicators of Clinical Severity: Need for artificial respiratory support or hemodynamic support (mechanical ventilation, ECLS)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV 2</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A blood sample will be collected in an EDTA tube for biomarker analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study aims to enroll patients 18 years or older, presenting to Emergency Rooms or&#xD;
        COVID-19 Assessment Centers with clinical suspicion of COVID-19 infection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients presenting with clinical suspicion of COVID-19 infection, as per UHN case&#xD;
             definition at the time of presentation&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Ability to provide verbal informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are not suspected of COVID-19 infection, as per UHN definition at the&#xD;
             time of presentation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahid Husain, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sharaniyaa Balachandran</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>6549</phone_ext>
    <email>sharaniyaa.balachandran@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharaniyaa Balachandran</last_name>
      <email>sharaniyaa.balachandran@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Shahid Husain, MD MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

